Taking the fight directly to the tumor
Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.
Arming the Immune System to Fight Cancer
Our core technology platform continues to advance through clinical trials for various cancers.
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
The Jersey factor: Why did OncoSec Medical, a leader in immunotherapy, relocate to N.J.?
Clinical trials of today may power
the medical advances of tomorrow.
LEARN MORE ABOUT OUR CURRENT CLINICAL TRIALS